## PIHLAJALINNA

Health Care/Finland, August 10, 2020 Preview

## Pandemic hampers non-urgent healthcare

Pihlajalinna reports its Q2'20E result on this week's Friday, 14<sup>th</sup> of August. We expect the COVID-19 and the movement restrictions have continued to hamper Pihlajalinna's business especially in April but the situation should have started to normalize. The tender offer by Mehiläinen is still being under review of the FCCA. We keep our rating "HOLD" and TP of EUR 16.0 intact.

### Expecting weak demand in non-urgent healthcare


Pihlajalinna's operations were heavily impacted by the emergency laws that came into force in mid-March. We expect to see the most negative impacts in April as especially the demand of non-urgent healthcare and oral healthcare started rapidly to decrease in late March. The management indicated earlier in H1 that the complete outsourcings and other fixed-priced invoicing have supported the company during the unexceptional times as the profitability of these kinds of contracts normally remains stable, even during times of lower demand. The demand of housing services for the elderly and recruitment services should also remain relatively stable.

### Still waiting for the FCCA's decision

We expect the customer flows have started slowly to recover. However, we expect to see better improvement later in H2'E as the pent-up demand of social services and non-urgent healthcare should normalize after the restrictions were lifted. The visibility of H2E remains blurry and the demand is depended on the pandemic situation. The tender offer by Mehiläinen is still being under review of the FCCA and the second phase investigation should be ready by the end of August. If approved, the process is expected to be completed during Q3'20E.

### "HOLD" with TP of EUR 16.0

We have only made minor adjustments to our estimates. We expect Q2'20E revenue of EUR 112.1m (-13.6% y/y) and adj. EBIT of EUR 0.2m (EUR 2.1m in Q2'19). We expect 20E revenue of EUR 517m (-0.3% y/y) and adj. EBIT of EUR 22.3m (6.7% y/y). We keep our rating "HOLD" and TP of EUR 16.0 intact.



Share price, EUR (Last trading day's closing price) Target price, EUR	14.55 16.0
larget price, Lon	10.0
Latest change in rating	11-May-20
Latest report on company	11-May-20
Research paid by issuer:	YES
No. of shares outstanding, '000's	22,620
No. of shares fully diluted, '000's	22,620
Market cap, EURm	329
Free float, %	79.0
Exchange rate	0.000
Reuters code	PIHLIS.HE
Bloomberg code	PIHLIS FH
Average daily volume, EURm	na.
Next interim report	14-Aug-20
Web site	investors.pihlajalinna.fi
Analyst	Anna-Liisa Rissanen
E-mail	annaliisa.rissanen@evli.com
Telephone	+358401579919

### BUY HOLD SELL

5	,									
KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2018	487.8	14.4	3.0%	-74.5	0.20	42.4	0.8	27.1	-38.2	0.10
2019	518.7	20.9	4.0%	9.6	0.47	32.3	1.1	26.6	2.8	0.00
2020E	517.0	22.3	4.3%	2.7	0.47	30.6	1.0	24.0	0.8	0.16
2021E	557.2	33.0	5.9%	16.4	0.86	17.0	0.9	15.8	5.0	0.28
2022E	573.9	37.3	6.5%	21.8	1.04	14.0	0.9	13.5	6.6	0.34
Market cap	o, EURm		329 G	earing 2020E,	o%		164.4 CAGR	EPS 2019-2	2,%	30.0
Net debt 2	020E, EURm		191 P	rice/book 2020	ЭE		3.0 CAGR	sales 2019-	22, %	3.4
Enterprise	value, EURm		535 D	ividend yield 2	2020E, %		1.1 ROE 2	2020E, %		10.1
Total asset	s 2020E, EURn	n	428 T	ax rate 2020E,	0/0		19.2 ROCE	2020E, %		6.7
Goodwill 2	020E, EURm		174 E	quity ratio 202	20E, %		27.2 PEG, I	P/E 20/CAGR		1.5

All the important disclosures can be found on the last pages of this report.

# PIHLAJALINNA

## Health Care/Finland, August 10, 2020

Preview

		Estima	ates									
Net sales	2017	2018	Q1'19	Q2'19	Q3'19	Q4'19	2019	Q1'20	Q2'20E	Q3'20E	Q4'20E	2020E
Corporate Customers	82.6	103.7	31.6	30.3	27.0	32.8	121.7	32.9	25.6	30.1	36.5	125.1
of which insurance companies	26.6	25.2	7.1	6.7	5.9	7.9	27.6	8.3	6.2	7.4	9.4	31.4
of which other corporates	56.0	78.5	24.5	23.6	21.1	24.9	94.1	24.6	19.4	22.7	27.1	93.8
Private Customers	67.9	92.1	26.5	25.6	21.1	24.9	98.1	23.5	11.5	23.2	27.4	85.6
Public sector customers	330.5	349.7	89.3	89.6	90.0	91.9	360.8	92.6	91.0	92.3	94.2	370.1
Total	424.0	487.8	132.5	129.7	122.7	133.8	518.6	133.0	112.1	129.9	142.0	517.0
Net sales growth												
Corporate Customers	-	25.5%	20.6%	19.6%	18.4%	11.6%	17.3%	4.1%	-15.3%	11.5%	11.4%	2.9%
Private Customers	-	35.6%	19.4%	5.1%	0.5%	1.2%	6.5%	-11.3%	-55.0%	10.0%	10.0%	-12.7%
Public sector customers	-	5.8%	4.9%	-0.8%	5.0%	3.7%	3.2%	3.7%	1.6%	2.6%	2.5%	2.6%
Total	6.2%	15.0%	11.1%	3.5%	5.5%	5.4%	6.3%	0.4%	-13.6%	5.9%	6.2%	-0.3%
Adj. EBITDA (group)	34.0	45.9	12.6	10.8	17.4	14.4	55.2	12.7	9.1	19.1	16.5	57.3
Adj. EBITDA-margin (group)	8.0%	9.4%	9.5%	8.3%	14.2%	10.8%	10.6%	9.5%	8.1%	14.7%	11.6%	11.1%

Source: Pihlajalinna, Evli Research

### Valuation

	Security	MCAP	EV/EBITDA	EV/EBITDA	ev/ebitda	EV/EBIT	EV/EBIT	EV/EBIT	P/E	P/E	P/E
PIHLAJALINNA PEER GROUP	identifier	Local FX	20	21	22	20	21	22	20	21	22
Ambea AB	AMBEA-SE	5137	8.2x	6.8x	6.1x	17.8x	13.8x	11.9x	12.3x	9.2x	8.3x
Attendo AB	ATT-SE	7228	9.6x	8.4x	7.6x		21.9x	18.2x	62.4x	24.8x	17.1x
CareTech Holdings PLC	CTH-GB	506	9.6x	8.6x	7.9x	13.1x	11.3x	9.8x	11.0x	9.5x	8.6x
Fresenius SE & Co. KGaA	FRE-DE	21602	6.2x	5.6x	5.0x	9.5x	8.4x	7.5x	12.0x	10.7x	9.9x
Georgia Healthcare Group Plc	GHG-GB	92									
GHP Specialty Care AB	GHP-SE	1370	9.4x	8.2x	7.7x	21.8x	17.3x	16.1x	32.5x	24.1x	22.4x
Humana AB	HUM-SE	2705	7.8x	7.1x	6.6x	14.0x	12.4x	11.3x	11.2x	9.8x	8.9x
Korian SA	KORI-FR	2661	8.8x	7.7x	7.7x	24.8x	19.5x	18.7x	29.4x	17.0x	14.5x
LNA Sante SA	LNA-FR	490	10.7x	9.6x	8.7x	23.5x	19.3x	17.1x	27.1x	19.6x	17.8x
Mediclinic International Plc	MDC-GB	1962	10.1x	7.2x	6.6x	19.3x	12.0x	10.9x	22.4x	10.6x	9.8x
Orpea SA	ORP-FR	6796	16.1x	14.2x	13.1x	34.1x	28.3x	26.3x	36.9x	26.0x	23.6x
RHON-KLINIKUM AG	RHK-DE	1171							67.3x	40.7x	
Spire Healthcare Group PLC	SPI-GB	341	9.6x	8.3x	7.2x	23.5x	17.4x	13.9x			25.3x
Terveystalo Oy Class A	TTALO-FI	1220	11.9x	9.2x	8.0x	31.0x	18.0x	14.7x	31.1x	17.9x	15.0x
Peer Group Median		3910	9.6x	8.2x	7.6x	21.8x	17.3x	14.3x	28.3x	17.4x	14.8x
Peer Group Average		1666	9.8x	8.4x	7.7x	21.1x	16.6x	14.7x	29.6x	18.3x	15.1x
Pihlajalinna (Evli est.)		329	9.3x	7.5x	6.9x	24.0x	15.8x	13.5x	30.6x	17.0x	14.0x
Pihlajalinna premium/discount to peer mediar			-2 %	-9 %	-10 %	10 %	-9 %	-6 %	8%	-3 %	-5 %

rınıajaıınna premium/discount to peer media Source: Factset, Evli Research

# PIHLAJALINNA

# Health Care/Finland, August 10, 2020

Preview

INTERIM FIGURES												
EVLI ESTIMATES, EURm	2019Q1	2019Q2	2019Q3	2019Q4	2019	202001	2020Q2E	2020Q3E	2020Q4E	2020E	2021E	2022E
Net sales	132.5	129.7	122.7	133.8	518.7	133.0	112.1	129.9	142.0	517.0	557.2	573.9
EBITDA	12.5	10.9	17.4	14.3	55.1	12.7	9.1	19.1	16.5	57.3	69.7	73.5
EBITDA margin (%)	9.4	8.4	14.2	10.7	10.6	9.5	8.1	14.7	11.6	11.1	12.5	12.8
EBIT	3.9	2.1	9.3	5.6	20.9	4.2	0.2	10.3	7.6	22.3	33.0	37.3
EBIT margin (%)	2.9	1.6	7.6	4.2	4.0	3.2	0.2	7.9	5.4	4.3	5.9	6.5
Net financial items	-1.0	-1.0	-1.0	-1.0	-4.0	-1.4	-1.3	-1.3	-1.3	-5.3	-5.0	-4.0
Pre-tax profit	2.9	1.1	8.3	4.6	16.9	2.8	-1.1	9.0	6.3	17.0	28.0	33.3
Tax	-0.7	-0.3	-0.3	-0.6	-1.9	-0.6	0.3	-1.7	-1.2	-3.3	-5.6	-6.7
Tax rate (%)	24.1	27.3	3.6	13.0	11.2	21.4	26.6	19.5	19.0	19.2	20.0	20.0
Net profit	1.8	-0.1	6.6	2.4	10.7	2.1	-0.8	6.0	3.4	10.7	19.4	23.5
EPS	0.08	0.00	0.29	0.11	0.47	0.09	-0.03	0.27	0.15	0.47	0.86	1.04
EPS adjusted (diluted no. of shares)	0.08	0.00	0.29	0.11	0.47	0.09	-0.03	0.27	0.15	0.47	0.86	1.04
Dividend per share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.28	0.34
SALES, EURm												
Corporate Customers	31.6	30.3	27.0	32.8	121.7	32.9	25.6	30.1	36.5	125.1	143.0	147.3
Private Customers	26.5	25.6	21.1	24.9	98.1	23.5	11.5	23.2	27.4	85.6	95.9	98.7
Public sector customers	89.3	89.6	90.0	91.9	360.8	92.6	91.0	92.3	94.2	370.1	383.5	395.0
Eliminations	-14.9	-15.7	-15.4	-15.8	-61.8	-16.0	-16.0	-15.7	-16.2	-63.9	-65.2	-67.1
Total	132.5	129.7	122.7	133.8	518.7	133.0	112.1	129.9	142.0	517.0	557.2	573.9
SALES GROWTH, Y/Y %												
Corporate Customers	14.1	27.1	8.9	11.6	15.1	4.1	-15.3	11.5	11.4	2.9	14.3	3.0
Private Customers	19.4	5.1	1.0	1.2	6.6	-11.3	-55.0	10.0	10.0	-12.7	12.0	3.0
Public sector customers	6.9	-2.5	7.5	3.7	3.8	3.7	1.6	2.6	2.5	2.6	3.6	3.0
Eliminations	4.9	6.8	17.6	1.3	7.3	7.4	2.0	2.0	2.3	3.4	2.0	3.0
Total	11.2	3.5	5.5	5.4	6.3	0.4	-13.6	5.9	6.1	-0.3	7.8	3.0
EBIT, EURm												
Group	3.9	2.1	9.3	5.6	20.9	4.2	0.2	10.3	7.6	22.3	33.0	37.3
Total	3.9	2.1	9.3	5.6	20.9	4.2	0.2	10.3	7.6	22.3	33.0	37.3
EBIT margin, %											<u> </u>	
Total	2.9	1.6	7.6	4.2	4.0	3.2	0.2	7.9	5.4	4.3	5.9	6.5

# PIHLAJALINNA

# Health Care/Finland, August 10, 2020

Preview

INCOME STATEMENT, EURm	2015	2016	2017	2018	2019	2020E	2021E	2022E
Sales	213.4	399.1	424.0	487.8	518.7	517.0	557.2	573.9
Sales growth (%)	43.3	87.0	6.2	15.0	6.3	-0.3	7.8	3.0
EBITDA	12.7	29.4	34.3	45.9	55.1	57.3	69.7	73.5
EBITDA margin (%)	6.0	7.4	8.1	9.4	10.6	11.1	12.5	12.8
Depreciation	-8.0	-12.8	-14.2	-31.5	-34.2	-35.0	-36.6	-36.2
EBITA	4.7	16.6	20.1	14.4	20.9	22.3	33.0	37.3
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	4.7	16.6	20.1	14.4	20.9	22.3	33.0	37.3
EBIT margin (%)	2.2	4.2	4.7	3.0	4.0	4.3	5.9	6.5
Reported EBIT	3.9	15.1	19.2	13.8	10.2	21.9	33.0	37.3
EBIT margin (reported) (%)	1.8	3.8	4.5	2.8	2.0	4.2	5.9	6.5
Net financials	-2.3	-1.2	-1.4	-3.8	-4.0	-5.3	-5.0	-4.0
Pre-tax profit	2.4	15.4	18.7	10.6	16.9	17.0	28.0	33.3
Taxes	-0.1	-3.0	-3.4	-2.7	-1.9	-3.3	-5.6	-6.7
Minority shares	-0.8	-2.7	-4.6	-3.3	-4.3	-3.0	-3.1	-3.1
Net profit	0.7	8.2	9.8	4.0	0.0	10.3	19.4	23.5
Cash NRIs	-0.8	-1.5	-0.9	-0.6	-10.7	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	-0.4	0.0	0.0
BALANCE SHEET, EURm	0.0	0.0	0.0	0.0	0.0	0.1	0.0	
Assets								
Fixed assets	69	67	83	68	74	69	67	67
Goodwill	76	92	104	170	174	174	174	174
Right of use assets	0	0	0	116	108	109	117	121
Inventory	2	2	2	3	2	3	3	3
Receivables	20	27	25	40	47	32	34	35
Liquid funds	15	27	37	36	27	36	39	40
Total assets	185	218	254	437	438	428	440	445
Liabilities	100	210	234	437	430	420	440	445
Shareholder's equity	92	98	100	121	101	111	127	144
Minority interest	52	3	6	9	5	5	5	5
Convertibles	0	3 0	0	9	5 0	5 0	5	5
Lease liabilities	0	0	0				117	
				119	114	109		121
Deferred taxes	5 42	6	6 77	6 99	6	6	6 101	6
Interest bearing debt		52			107	119		83
Non-interest bearing current liabilities	42	55	62	80	102	75	81	83
Other interest-free debt	3	3	3	3	2	2	2	2
Total liabilities	185	217	254	437	438	428	440	445
CASH FLOW, EURm							70	
+ EBITDA	13	29	34	46	55	57	70	73
- Net financial items	-2	-1	-1	-4	-4	-5	-5	-4
- Taxes	0	-2	-5	-5	-4	-3	-6	-7
- Increase in Net Working Capital	9	8	7	2	14	-12	3	1
+/- Other	-2	-1	0	-11	-15	-3	-3	-3
= Cash flow from operations	18	32	35	27	46	34	59	61
- Capex	-48	-5	-10	-23	-36	-31	-43	-39
- Acquisitions	0	-22	-17	-79	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-30	6	8	-74	10	3	16	22
+/- New issues/buybacks	82	-1	-2	24	-22	0	0	0
- Paid dividend	0	0	-3	-3	-2	0	-4	-6
+/- Other	-48	7	7	53	5	7	-10	-14
Change in cash	4	12	10	-1	-9	9	3	1

# PIHLAJALINNA

# Health Care/Finland, August 10, 2020

Preview

KEY FIGURES	2016	2017	2018	2019	2020E	2021E	2022E
M-cap	380	275	195	346	329	329	329
Net debt (excl. convertibles)	25	40	181	194	191	179	163
Enterprise value	416	325	391	557	535	521	504
Sales	399	424	488	519	517	557	574
EBITDA	29	34	46	55	57	70	73
EBIT	17	20	14	21	22	33	37
Pre-tax	15	19	11	17	17	28	33
Earnings	10	11	5	11	11	19	24
Equity book value (excl. minorities)	98	100	121	101	111	127	144
Valuation multiples							
EV/sales	1.0	0.8	0.8	1.1	1.0	0.9	0.9
EV/EBITDA	14.2	9.5	8.5	10.1	9.3	7.5	6.9
EV/EBITA	25.1	16.2	27.1	26.6	24.0	15.8	13.5
EV/EBIT	25.1	16.2	27.1	26.6	24.0	15.8	13.5
EV/OCF	12.9	9.3	14.3	12.1	16.0	8.8	8.3
EV/FCFF	66.9	19.3	-11.7	20.3	20.7	10.6	10.0
P/FCFE	67.8	35.7	-2.6	36.0	122.6	20.1	15.1
P/E	39.1	25.7	42.4	32.3	30.6	17.0	14.0
P/B	3.9	2.7	1.6	3.4	3.0	2.6	2.3
Target EV/EBITDA	0.0	0.0	0.0	0.0	9.7	7.8	7.2
Target EV/EBIT	0.0	0.0	0.0	0.0	25.0	16.5	14.2
Target EV/FCF	0.0	0.0	0.0	0.0	208.0	33.3	24.3
Target P/B	0.0	0.0	0.0	0.0	3.2	2.8	2.5
Target P/E	0.0	0.0	0.0	0.0	33.7	18.7	15.4
Per share measures	0.0	0.0	0.0	0.0	000	10.7	10.1
Number of shares	20,613	20,613	22,620	22,620	22,620	22,620	22,620
Number of shares (diluted)	20,613	20,613	22,620	22,620	22,620	22,620	22,620
EPS	0.47	0.52	0.20	0.47	0.47	0.86	1.04
Operating cash flow per share	1.57	1.69	1.21	2.03	1.48	2.62	2.70
Free cash flow per share	0.27	0.37	-3.29	0.42	0.12	0.72	0.96
Book value per share	4.74	4.87	5.36	4.47	4.93	5.63	6.38
Dividend per share	0.15	0.16	0.10	0.00	0.16	0.28	0.34
Dividend payout ratio, %	31.9	30.8	49.2	0.0	33.0	33.0	33.0
Dividend yield, %	0.8	1.2	1.2	0.0	1.1	1.9	2.4
FCF yield, %	1.5	2.8	-38.2	2.8	0.8	5.0	6.6
Efficiency measures				-			
ROE	10.2	10.8	4.2	9.6	10.1	16.2	17.3
ROCE	11.7	12.2	5.4	6.2	6.7	9.5	10.6
Financial ratios		1212	0.1	0.2	0.7	0.0	10.0
Inventories as % of sales	0.5	0.5	0.5	0.4	0.5	0.5	0.5
Receivables as % of sales	6.7	5.9	8.2	9.1	6.2	6.2	6.2
Non-interest bearing liabilities as % of sales	13.8	14.6	16.3	19.7	14.5	14.5	14.5
NWC/sales, %	-6.9	-8.4	-8.0	-10.2	-7.9	-7.9	-7.9
Operative CAPEX/sales, %	-0.3	2.4	4.6	7.0	6.0	7.7	6.8
CAPEX/sales (incl. acquisitions), %	-4.1	-1.6	-11.6	7.0	6.0	7.7	6.8
	7.1		-0.7	0.5	0.5	0.7	0.7
	0.2	0.5			0.0	0.7	0.7
FCFF/EBITDA	0.2	0.5 1.2				26	2.2
FCFF/EBITDA Net debt/EBITDA, book-weighted	0.8	1.2	3.9	3.5	3.3	2.6	
FCFF/EBITDA Net debt/EBITDA, book-weighted Debt/equity, market-weighted	0.8 0.1	1.2 0.3	3.9 0.5	3.5 0.3	3.3 0.4	0.3	2.2 0.3
FCFF/EBITDA Net debt/EBITDA, book-weighted	0.8	1.2	3.9	3.5	3.3		

## PIHLAJALINNA Health Care/Finland, August 10, 2020 Preview

COMPANY DESCRIPTION: Pihlajalinna is the 3rd largest private social welfare and healthcare service provider in Finland offering a wide selection of services to private individuals, businesses, insurance companies and public sector entities, such as municipalities and joint municipal authorities. In its private clinics and hospitals Pihlajalinna provides general practitioner services, specialized care, emergency and on-call services, a wide range of surgical services, occupational healthcare and dental care. Pihlajalinna is the market leader in complete social and healthcare outsourcings in Finland.

INVESTMENT CASE: The demand for private social and healthcare services is growing due to ageing population and increasing pressure on public healthcare spending, offering Pihlajalinna growth opportunities in primary care as well as in specialized care. Profitability improvement stems from increased volumes and better utilization rate of the clinics.

OWNERSHIP STRUCTURE	SHARES	EURm	%
Lähitapiola Keskinäinen Vakuutusyhtiö	3,481,641	50.658	15.4%
Mww Yhtiö Oy	2,309,010	33.596	10.2%
Fennia Mutual Insurance Company	1,998,965	29.085	8.8%
Tapiola Keskinäinen Henkivakuutusyhtiö	1,891,385	27.520	8.4%
Elo Pension Company	1,267,161	18.437	5.6%
Niemistö Leena Katriina	703,475	10.236	3.1%
Ilmarinen Mutual Pension Insurance Company	490,000	7.130	2.2%
Fondita Nordic Micro Cap	470,000	6.838	2.1%
Fennia Life Insurance Company Ltd	265,528	3.863	1.2%
Sijoitusrahasto Taaleritehdas Mikro Markka	260,000	3.783	1.1%
Ten largest	13,137,165	191.146	58%
Residual	9,482,970	137.977	42%
Total	22,620,135	329.123	100%

EARNINGS CALENDAR August 14, 2020 November 04, 2020

Q2 report Q3 report

### OTHER EVENTS

COMPANY MISCELLANEOUS	
CEO: Joni Aaltonen	Kehräsaari B, 33200 Tampere
CFO: Tarja Rantala	Tel:
IR: Marko Savolainen	

## PIHLAJALINNA Health Care/Finland, August 10, 2020

Preview

DEFINITIONS

P/E	EPS
Price per share	Durfit haf an antipart it is and the set is a set of the set of the set
Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest Number of shares
P/BV	DPS
Price per share	Dividend for the financial period per share
Shareholders' equity + taxed provisions per share	
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working
	capital – Cash NRIs ± Other adjustments
EV (Enterprise value)	FCF (Free cash flow)
<b>N</b>	
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
Share of associated companies at market value	
EV/Sales	FCF yield, %
Enterprice volue	
Enterprise value Sales	Free cash flow
Jaics	Market cap
EV/EBITDA	Operative CAPEX/sales
,	
Enterprise value	Capital expenditure – divestments – acquisitions
Earnings before interest, tax, depreciation and amortization	Sales
EV/EBIT	Net working capital
LV/LDII	
Entermice value	Current accete _ aurent liabilities
Enterprise value Operating profit	Current assets – current liabilities
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt
	Number of shares
Total assets	Gearing
Balance sheet total	Net debt
	Equity
Div yield, %	Debt/Equity, %
Dividend per share	Interest bearing debt
Price per share	Shareholders' equity + minority interest + taxed provisions
	, , , ,
Payout ratio, %	Equity ratio, %
Total dividends	Shareholders' equity + minority interest + taxed provisions
Earnings before extraordinary items and taxes - income taxes + minority interest	Total assets – interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs	
Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
······································	
ROE, %	
Profit before extraordinary items and taxes – income taxes	
Shareholder's equity + minority interest + taxed provisions (average)	

## PIHLAJALINNA Health Care/Finland, August 10, 2020

Preview

#### Important Disclosures

Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at Analysts' recommendations and ratings revisions. Investment recommendations are defined as follows: Target price compared to share price Recommendation < -10 % SELL -10 - (+10) % HOLD > 10 % BUY ERP's investment recommendation of the analyzed company is updated at least 2 times per year. 58% 60% 50% 40% 27% 30% 20% 15% 10% 0% Sell Hold Buy

The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

#### Name(s) of the analyst(s): Rissanen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [10.08.2020, 08:30]. This report has been published on [10.08.2020, 09:35].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services. months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the. For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

## **PIHLAJALINNA** Health Care/Finland, August 10, 2020

Preview

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

# PIHLAJALINNA

### Health Care/Finland, August 10, 2020 Preview

Contact information					
SALES, TRADING AND RESEARCH	1				
Equity Sales		Trading		ETFs and Derivatives	
Ari Laine Lauri Ahokanto Niclas Henelius	+358 9 4766 9115 +358 9 4766 9117 +358 9 4766 9116	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120	Joachim Dannberg Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9130
Structured Investments		Equity Research			
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Anna-Liisa Rissanen	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 157 9919		
Evli Investment Solutions					
Johannes Asuja Markku Reinikainen	+358 9 4766 9205 +358 9 4766 9669				

**EVLI** BANK PLC

EVLI BANK PLC Aleksanterinkatu 19 A P.O. Box 1081 FIN-00101 Helsinki, FINLAND Phone +358 9 476 690 Fax +358 9 634 382 Internet www.evli.com E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001